Cleveland Clinic

This episode covers key trial results and presentations to keep an eye on as ADA 2026 approaches.

On IgAN Awareness Day, clinicians highlight earlier diagnosis, dynamic risk stratification, and emerging targeted therapies reshaping care.

This episode covers recent advancements in treating type 1 diabetes, including the Tandem AID system for pregnant women and teplizumab for adolescents.

ICI colitis linked to high rehospitalization, ICU use, and mortality even after therapy discontinuation.

Catch up on any data and perspectives presented at the American Association of Clinical Endocrinology Annual Meeting 2026.

April 2026 saw further updates from ACC.26, plus key trial results, guideline updates, and more.

New paired biopsy data show histologic regression after metabolic bariatric surgery in compensated MASH patients, challenging the irreversibility of cirrhosis.

Isaacs covers the range of AID devices currently available and approved for T2D, providing suggestions for implementation and continuous glycated hemoglobin monitoring.

Viral Shah, MD, joins the show to break down his AACE 2026 presentation on the benefits of using GLP-1 RAs in patients with T1D.

Elizabeth Bauer, MD, joins the show to discuss her AACE 2026 presentation on key updates in obesity management and nutrition.

Linda DiMeglio, MD, MPH, joins the show to discuss the growing movement towards screening and testing for T1D at an early stage.

Hanna explains the real-world barriers to implementing gene editing therapies in sickle cell disease.

Hanna describes the "freedom" patients with sickle cell disease reported after being treated with reni-cel, a one-time edited gene therapy.

This episode explores the launch and accessibility of FDA-approved oral GLP-1 orforglipron, including availability through Amazon Pharmacy's same-day delivery service.

Hanna, MD, shares results from reni-cel, a one-time gene editing therapy for patients with sickle cell disease.

Nissen discusses his post-hoc analysis of the SURPASS-CVOT trial, comparing the 2 drugs for a 6-component composite endpoint of cardiorenal outcomes.

Catch up on FDA decisions, new GLP-1 agonists, and more.

Jessica Castle, MD, joins the show to give a peek behind the curtain at Dexcom’s latest advancements in CGM technology.

This episode covers the March 26th approval of Awiqli for T2D, highlighting its high concentration and once-weekly administration.

Catch up on the most impactful trial readouts to come out of ACC 2026.

Laffin discusses results from the Kardinal study, which investigated a single dose of tonlamarsen followed by placebo against monthly tonlamarsen treatment in hypertension.

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

Corey Cavanaugh, DO, and Abdallah Geara, MD, separately share their perspectives on the clinical clues for IgAN diagnosis, including hypertension and microscopic hematuria.

This episode features discussion around 3 recent announcements from Novo Nordisk, Eli Lilly, and Structure Therapeutics.

Even Routine Urinalysis Can Reveal Hidden IgA Nephropathy, Especially in Young Adults

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline results from the TRIUMPH-4 trial, demonstrating retatrutide's efficacy in promoting weight loss.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recently published trial results and what they mean for Eli Lilly’s newest GLP-1 molecule.

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval and what it means for Wegovy 7.2 mg in the US.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Lilly’s groundbreaking new Zepbound administration option.